Πλοήγηση ανά Θέμα "ofatumumab"
Αποτελέσματα 1-3 από 3
-
Anti-cd20 agents for multiple sclerosis: Spotlight on ocrelizumab and ofatumumab
(2020)Until recently, in the pathogenesis of Multiple Sclerosis (MS), the contribution of B cells has been largely underestimated, and the disease was considered a T-cell-mediated disorder. However, newer evidence shows that B ... -
B-Cell Targeted Therapies in Patients with Multiple Sclerosis and Incidence of Headache: A Systematic Review and Meta-Analysis
(2022)Background: Multiple Sclerosis treatment with B-cell targeted therapies may be associated with an increased incidence of headache. We aimed to find and compare the association of B-cell targeted therapies with the incidence ... -
Regulatory B and T lymphocytes in multiple sclerosis: friends or foes?
(2018)Current clinical experience with immunomodulatory agents and monoclonal antibodies in principle has established the benefit of depleting lymphocytic populations in relapsing–remitting multiple sclerosis (RRMS). B and T ...